COVID-19 resources & COVID-19 vaccine information

Sword Assay for Human IL-1β

Interleukin-1 is a pro-inflammatory cytokine that can be expressed in two separate isoforms: IL-1α and IL-1β.1 IL-1β is expressed by dendritic cells and acts through the TNFα signaling pathway to induce expression of several inflammatory cytokines2, 3; it has therefore been identified as both a biomarker for inflammation diagnosis and a target for inflammation therapy.
Current ELISAs lack the required sensitivity to quantify IL-1β in normal healthy donor serum for proper comparison with diseased individuals. Sword has changed that by developing a reagent based on the principle of Raman Resonance that can easily be inserted into a standard IL-1β ELISA with greatly enhanced sensitivity.
This Sword Assay has been optimized for use with the R&D Systems DuoSet ELISA for Human IL-1β (Catalog No. DY201). This protocol allows the user to use 50 µL sample sizes instead of 100 µL as specified in the DuoSet literature.

Assay Type:

Sandwich ELISA

Product #:

SB-HIL2301-05

See the Sword Performance Difference

Citations

  1. Weber A, et al: Interleukin-1beta (IL-1beta) processing pathway. Sci Signal 2010, 3:cm2.
  2. Luft T, et al: IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. Journal of immunology 2002, 168:713-22.
  3. Zhang et al: Interleukin-1beta induces macrophage inflammatory protein-1beta expression in human hepatocytes. Cell Immunol 2003, 226:45-53.

Ready to Optimize Your Assay?

Put Sword to the test. Give us 6 days and we’ll show you just how much we can boost your specific assay’s sensitivity, precision, and accuracy. We’ll even assess your first target assay free of charge.

Purchase this Assay

Contact the Sword team today to discuss how best to implement our Human IL-23 assay for your needs.

FAQs

Learn more about Sword’s patented technology and how it can be optimally configured for your specific matrix needs.